Ridgecrest Wealth Partners LLC Sells 7,120 Shares of Johnson & Johnson $JNJ

Key Points

• Ridgecrest Wealth Partners cut its Johnson & Johnson stake by 54.9% in Q4, selling 7,120 shares and leaving 5,855 shares valued at about $1.21 million.
• Insider selling has been notable—EVPs Vanessa Broadhurst and Timothy Schmid sold 6,197 and 22,623 shares respectively, with insiders offloading 30,142 shares (~$7.36M) over the past three months and owning roughly 0.16% of the stock.
• Market view is mixed: brokerages have raised and lowered ratings, MarketBeat shows a consensus of "Moderate Buy" with a $238.17 target, and J&J’s upcoming Q1 report is the key near-term catalyst.

Ridgecrest Wealth Partners LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 54.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,855 shares of the company's stock after selling 7,120 shares during the quarter. Ridgecrest Wealth Partners LLC's holdings in Johnson & Johnson were worth $1,212,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Campbell Deegan Wealth Management LLC boosted its stake in Johnson & Johnson by 1.6% during the 4th quarter. Campbell Deegan Wealth Management LLC now owns 2,990 shares of the company's stock valued at $619,000 after purchasing an additional 48 shares during the period. Centennial Wealth Advisory LLC boosted its stake in Johnson & Johnson by 2.2% during the 4th quarter. Centennial Wealth Advisory LLC now owns 2,284 shares of the company's stock valued at $473,000 after purchasing an additional 49 shares during the period. Gleason Group Inc. boosted its stake in Johnson & Johnson by 0.8% during the 4th quarter. Gleason Group Inc. now owns 6,390 shares of the company's stock valued at $1,322,000 after purchasing an additional 50 shares during the period. ACT Wealth Management LLC boosted its stake in Johnson & Johnson by 3.9% during the 4th quarter. ACT Wealth Management LLC now owns 1,399 shares of the company's stock valued at $290,000 after purchasing an additional 52 shares during the period. Finally, MBE Wealth Management LLC boosted its stake in Johnson & Johnson by 3.1% during the 4th quarter. MBE Wealth Management LLC now owns 1,740 shares of the company's stock valued at $360,000 after purchasing an additional 52 shares during the period. Institutional investors own 69.55% of the company's stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst price-target increase — J&J had a price-target raise to $267, a near-term bullish signal that can support the stock if earnings and guidance align. Article Title
• Positive Sentiment: Strong Innovative Medicines growth noted by investors/letters — Institutional commentary highlights J&J’s Innovative Medicines momentum as a core growth driver underpinning YTD gains and medium-term earnings resilience. Article Title
• Positive Sentiment: TECNIS PureSee IOL clinical/real-world data spotlight — New data presented at ASCRS highlight adoption potential for J&J’s recently FDA-approved intraocular lens, supporting the company’s ophthalmology growth narrative. Article Title
• Positive Sentiment: Steady index momentum — J&J is being noted for steady momentum within the Russell 1000, which can attract passive/index flows and support valuation. Article Title
• Neutral Sentiment: Q1 preview and analyst expectations — Multiple previews (Seeking Alpha, TipRanks) emphasize tomorrow’s Q1 print and guidance as the main near-term catalyst; analysts expect continued earnings but will watch revenue mix and guidance closely. Article Title Article Title
• Neutral Sentiment: Market backdrop — A broader tech-led rally (Nasdaq) and weekly earnings calendar may lift sentiment for large-cap cyclicals, but J&J’s move will hinge more on its own results than tape action. Article Title Article Title
• Negative Sentiment: Short-term pullback and volatility risk — Recent headlines note a 1.2% pullback and intraday weakness; with Q1 due imminently, any guidance miss or cautious commentary could push shares lower. Article Title
• Negative Sentiment: Comparative pressures from higher-growth peers — Coverage comparing J&J to faster-growth names (e.g., Lilly) frames a valuation-growth tradeoff that could limit upside if investors favor high-growth pharma exposure. Article Title

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares of the company's stock, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have commented on JNJ. Sanford C. Bernstein raised their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the stock a "market perform" rating in a research report on Friday, January 23rd. Freedom Capital downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 16th. UBS Group reiterated a "buy" rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Wall Street Zen downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. Finally, Wolfe Research raised their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the stock an "outperform" rating in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $238.17.

Johnson & Johnson Trading Down 0.2%

Shares of JNJ opened at $238.00 on Tuesday. Johnson & Johnson has a 1 year low of $146.12 and a 1 year high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The stock has a 50 day simple moving average of $241.44 and a 200-day simple moving average of $215.95. The stock has a market cap of $573.25 billion, a PE ratio of 21.54, a PEG ratio of 2.38 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion during the quarter. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.